- Home
- DTST vs NERV Comparison
DTST vs NERV Comparison
Compare DTST & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | NERV |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 269.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | DTST | NERV |
|---|---|---|
| Price | $4.05 | $6.73 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 9.6K | ★ 111.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 104.12 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $1.15 |
| 52 Week High | $5.44 | $12.46 |
Technical Indicators
Market Signals| Indicator | DTST | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 70.20 |
| Support Level | $3.74 | $1.70 |
| Resistance Level | $4.37 | $12.46 |
| Average True Range (ATR) | 0.18 | 0.49 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 32.26 | 69.93 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.